Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over

TA1088 - Final scope (PDF 165 KB)

TA1088 - NICE's response to comments on the draft scope and provisional stakeholder list (PDF 488 KB)

TA1088 - Equality impact assessment (scoping) (PDF 129 KB)

TA1088 - Final stakeholder list (PDF 156 KB)

TA1088 - Draft guidance document (PDF 248 KB)

TA1088 - DG Committee papers (PDF 8.89 MB)

TA1088 - DG Equality impact assessment (guidance development) (PDF 162 KB)

TA1088 - Final Draft Guidance document (PDF 249 KB)

TA1088 - FDG Equality impact assessment (guidance development) (PDF 138 KB)

TA1088 - Final Draft Guidance Committee papers (PDF 2.96 MB)

TA1088 - appeal decision (PDF 366 KB)

TA1088 - FDG2 document (PDF 304 KB)

TA1088 - FDG2 Committee papers (PDF 2.41 MB)

Final draft guidance

Final draft guidance (PDF 290 KB)

Committee papers (PDF 539 KB)